Dr. Reddy’s Q4 Review - Healthy Revenues; One-Offs Suppress Profits: ICICI Securities

BQ Prime’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BQ Prime’s subscribers an opportunity to expand their understanding of companies, sectors and the economy..ICICI Securities Report.Dr. Reddy’s Laboratories Ltd.’s Q4 FY22 performance was healthy with revenue growing 11.2% YoY to Rs 52.6 billion (our estimate: Rs 51.3 billion) driven by growth across markets. Domestic sales grew 14.7% YoY to Rs 9.7 billion. Despite pricing pressures, U.S. revenue grew 5.1% QoQ to $263 million on the back of new product launches and scale up of existing products. Dr. Reddy's recorded several one-offs during the quarter (sale of two brands in Russia and impairment on few assets). Adjusted Ebitda margin at 20.7% was marginally lower than our estimate of 21.5%. Adjusted profit after tax declined 31% YoY to Rs 3.2 billion. We expect growth momentum in branded generics business and new launches in U.S. in coming quarters to continue. .Click on the attachment to read the full report:.DISCLAIMERThis report is authored by an external party. BQ Prime does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BQ Prime..Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

Dr. Reddy’s Q4 Review - Healthy Revenues; One-Offs Suppress Profits: ICICI Securities

Dr. Reddy’s Q4 Review - Healthy Revenues; One-Offs Suppress Profits: ICICI Securities

Choose a plan